logo
Suicide prevention leader and senior researcher outline why lived experience is vital for national strategy

Suicide prevention leader and senior researcher outline why lived experience is vital for national strategy

When it comes to suicide prevention, Samantha McIntosh knows more than most.
With a lived experience of suicidality, a long career in suicide prevention and a recent foray into academia on the subject, the Darwin woman has seen multiple facets of what she described as a still highly stigmatised issue.
As opposed to coming from a purely clinical perspective, she says having both personal and professional experience of suicidality — defined as the risk of suicide, indicated by suicidal ideation — can be crucial to engaging with patients and devising solutions.
Ms McIntosh has long advocated for people with lived experience to be central when it comes to drafting strategies and other prevention efforts.
And governments and independent commissions are starting to agree.
According to a June 2025 report from the Productivity Commission, the federal government's National Mental Health and Suicide Prevention Agreement is failing to meet the mark.
While the expenditures of governments on mental health has grown by around 30 per cent over the past 10 years, suicide rates over that period of time remain unchanged.
The Productivity Commission recommended greater inclusion of people with lived and living experience of suicidality in drafting and implementing policy.
For Ms McIntosh, the recommendations present a rare opportunity for change.
At the other end of Australia — in the regional Victorian town of Warragul — Anton Isaacs, a senior lecturer at Monash University's School of Rural Health, has been helping bring Ms McIntosh's ideas to life.
"It's rare for somebody to have the kind of expertise that Sam has," he said.
"She has the lived experience of suicidality, she has supported people who have attempted to take their lives, she has been a suicide prevention worker and she worked in leadership positions in programs."
The pair recently co-authored a peer-reviewed perspective paper on challenges to suicide prevention, merging Dr Isaacs's experience of drafting strategies with Ms McIntosh's experience of navigating them.
It focuses on broadly on stigma surrounding suicide, diving specifically into the careless reporting of suicide in news media, access points of care, and a general lack of understanding in the community when it comes to helping at-risk individuals access services.
Dr Isaacs said the work being done is just the beginning, but he noted that integrating lived experience into suicide prevention would require the sector to confront some "basic truths".
"Suicide has traditionally fallen under the remit of mental health services, which are clinical services. In clinical medicine, the focus is to arrive at a diagnosis and treat it," he said.
"In suicide prevention, the focus is not on arriving at a diagnosis and treating, the focus is care and compassion — that is not clinical.
Ms McIntosh agreed, and said the key to effective suicide prevention was a matter of striking the right balance.
"That combination of clinical and lived experience doesn't exist in a lot of places," she said.
Last month, the Mental Health Commission published its National Suicide Prevention Strategy for the next 10 years, which emphasised the inclusion of people with lived experience in prevention efforts.
"People with lived and living experience have the greatest insights into what works, what does not work, and what is missing in suicide prevention," it reads.
But Dr Isaacs and Ms McIntosh explained that such inclusion must be considered and meaningful, rather than a "tick-box exercise".
"If people don't consider lived experience to be central or core to their work, then they don't give it the importance that they need," Dr Isaacs said.
"If that happens, the people with lived experience at the table will feel disillusioned or could be re-traumatised."
Ms McIntosh also said any plan to centralise lived experience in prevention efforts would have to be tailored to the needs of various communities, especially in a unique landscape like the NT.
"The geographical layout of the territory itself poses problems," she said
"We know that there's workforce challenges across the [NT] in all sectors and being able to support the diversity of the territory and communities is also something that we face."
While the obstacles to change are numerous, she said there was plenty of support across the sector to make lived experiences central to new prevention strategies.
"I think that they would be more successful, I think that they would be more achievable, and I think you would have higher client rates," Ms McIntosh said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Labor looks to speed up PBS listings amid calls from lobby groups
Labor looks to speed up PBS listings amid calls from lobby groups

News.com.au

time8 minutes ago

  • News.com.au

Labor looks to speed up PBS listings amid calls from lobby groups

Health Minister Mark Butler says he is looking at recommendations to speed up medicine approvals amid pressure from lobbyists both within Australia and in the US. Medicines Australia has repeatedly highlighted that Australia lags behind comparable countries in listing new medicines on the Pharmaceutical Benefits Scheme (PBS) – a list of federally subsidised medicines. It takes an average of 466 days from when the Therapeutic Goods Administration approves a medicine to when it becomes affordable on the PBS, according to the peak body. This is much longer than in the UK and Canada, for example. The lengthy timeline has also angered the Pharmaceutical Research and Manufacturers of America (PhRMA), which has framed the PBS as a 'non-tariff trade barrier' that harms American companies in representations to the Trump administration. Lengthy PBS listing times is among PhRMA's core criticisms. Mr Butler said on Thursday he would look at Medicines Australia's recommendations to make the 'approvals system quicker'. 'We're getting an enormous number of new medicining coming on to the market,' he told the ABC. 'We're living through a turbocharged period of discovery bringing more and more new medicine, so making sure that we can assess them and approve them very quickly to get them into patients as quickly as possible is something I've said is a real priority for us this term.' Because the PBS compels drugmakers to negotiate prices with the federal government, PhRMA has accused Australia of 'freeloading' on US-funded research and development. Meanwhile, American consumers pick up the bill, according to the lobby group. 'The medicines industry, understandably, given their interest, want to make prices higher as well, so there will be a bit of a debate about how we do that,' Mr Butler said. 'But I'm very much on the page of getting medicines more quickly into our system, our PBS system. 'It's a terrific system and we're trying to make medicines cheaper at the same time for Australians.' PhRMA has explicitly urged the Trump administration to 'leverage ongoing trade negotiations' to influence Australia's PBS policies. Mr Butler has echoed Anthony Albanese and fellow senior government ministers in ruling out any 'compromise' on the system as part of tariff talks. For the moment, Donald Trump's concern with the sector appears to be largely focused on bringing down prices in the US rather than punishing allies for having cheaper medicines. A RAND Corporation report found that Americans pay nearly four times more than Australians for medicines and about three times more than the average in other developed economies. The answer, according to the US President, is to make pharmaceuticals in the US. In a warning shot to firms, Mr Trump this week threatened to slap tariffs of up to 250 per cent on foreign-made products. With Australian pharma exports to the US worth more than $2bn in 2024, it would hit producers Down Under hard. Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous products, such as bandages. 'We'll be putting (an) initially small tariff on pharmaceuticals,' Mr Trump told US business news channel CNBC. 'In one year, 1½ years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country.' He did not say what the initial rate would be, but earlier in the year he said duties on the sector would start from 25 per cent.

20th Anniversary Collection: How power and fear play out in the dentist's chair
20th Anniversary Collection: How power and fear play out in the dentist's chair

ABC News

time2 hours ago

  • ABC News

20th Anniversary Collection: How power and fear play out in the dentist's chair

Sharonne Zaks grew up in a family of dentists, and when she too became a dentist, she developed an empathetic relationship with her patients, never judging them even if they'd avoided the dentist for years. A patient named Anna profoundly changed Sharonne's understanding of a patient's experience in the dentist's chair. Sharonne realised that for those who have been through a sexual assault or trauma, the extreme powerlessness of being treated at the dentist can be highly triggering. Sharonne undertook study into the area, and began a new regime to treat survivors in her own practice. She then began explaining what she'd found about the power dynamic between dentist and patient, to her own colleagues. Further information 2025 update: Sharonne regularly presents on trauma-informed care to groups across the dental profession and beyond, including lawyers, nurses, doctors and carers. Trauma-informed dental knowledge and skills have recently been made core competencies for all newly qualified dentists by the Australian Dental Council. You can read all about the Conversations origin story on the ABC News website.

Assistive tech targets market growth while improving lives
Assistive tech targets market growth while improving lives

News.com.au

time3 hours ago

  • News.com.au

Assistive tech targets market growth while improving lives

Demand for assistive technologies on the rise with growing global ageing population and awareness of disability inclusion Cochlear one of most high-profile ASX assistive technologies companies with legacy spanning more than 40 years Control Bionics helping thousands around the world communicate and connect in ways once thought impossible With a rising global ageing population and awareness of disability inclusion growing, demand is increasing for technologies that help people maintain independence and improve quality of life. Assistive technologies go beyond medical diagnostics or treatment by directly enabling individuals to hear, see, communicate and perform daily activities they might otherwise struggle to do. And while assistive technology delivers clear social benefits and aligns with ESG goals, it's also targeting a rapidly expanding market. Globally the assistive tech market was valued at ~US$22.9 billion in 2023 and is projected to reach US%36.6 bn by 2033, reflecting a compound annual growth rate (CAGR) of 4.8% throughout the decade. In Australia, the assistive technology sector is projected to expand from ~US$720 million in 2023 to more than US$1.7bn by 2030, driven by demographic shifts such as an ageing population and rising prevalence of long-term disabilities. Australia's substantial healthcare expenditure is also considered a pivotal driver for demand in the Australian disabled and elderly assistive device market. Global pioneer in hearing implant technology From restoring communication for those with severe disabilities to preserving vision and enhancing hearing, Australian companies have a proud history in assistive technologies with ASX blue-chip Cochlear (ASX:COH) one of the most high profile. Cochlear stands as one of the world's foremost innovators in assistive hearing technology with a legacy spanning more than 40 years. Cochlear implants and bone conduction devices are life-changing products, which have enabled hundreds of thousands of people globally across all ages to hear and communicate more effectively. Cochlear CEO and president Dig Howitt told Stockhead the organisation continued to progress new technology and care models, having recently launched the Cochlear Nucleus Nexa System, the world's first and only smart implant system. "The Nucleus Nexa Implant is the outcome of a 20 year investment in R&D and is the first cochlear implant to run its own firmware," he said. Howitt said similar to smartphones, the implant firmware could be updated to enable new features and access future innovations. "Recipients will now have access to a better hearing experience with both implant and sound processor updates," he said. "The Nucleus Nexa System builds upon Cochlear's industry-leading portfolio of electrodes, which are designed to optimise the electrode-neural interface and protect cochlea health and opens the door to even greater hearing potential for patients into the future." Enhancing sound in real-world situations While Cochlear may dominate the implantable hearing device market Brisbane-based Audeara (ASX:AUA) is carving out its own space in personalised listening solutions that sit between consumer audio products and clinical hearing aids. The flagship Audeara headphones and TV bundles the company started with use built-in hearing checks to create tailored sound profiles, ensuring clearer, enhanced listening experiences. Audeara managing director James Fielding told Stockhead the features made the devices valuable for those with mild to moderate hearing loss, or for people using cochlear implants and hearing aids who got an incredible entertainment experience when the sound was tailored to their needs. Building its portfolio Audeara launched Buds into its clinic networks this year. Unlike conventional hearing aids, Buds focus on enhancing the sound in real world situations like a busy cafe while also staying true to their entertainment focus, enhancing calls, TV and music. "We believe assistive technology should enhance the human experience without compromise," Fielding said. "At Audeara, our personalised hearing solutions empower people to connect more deeply with music, conversations and entertainment, regardless of their hearing ability." The technology also supports accessibility through government funding programs including NDIS, DVA and the Hearing Services Program, broadening its reach and affordability. With distribution in 1,500 clinics across Australia and more than 3,000 globally, including partnerships with major networks like Specsavers and Amplifon, Audeara is well positioned to capture growth in a market that's both socially impactful and commercially attractive. "The future of assistive technology is about inclusion, not limitation," Fielding said. "Audeara's mission is to ensure that hearing health solutions are seamlessly integrated into everyday life, combining clinical credibility with consumer-level accessibility." 'Giving communication back for more than two decades' Control Bionics (ASX:CBL) CEO Jeremy Steele describes the assistive technology medical device company as "sitting at the intersection of neuroscience and accessibility". "For more than 20 years, Control Bionics has been at the forefront of assistive technology innovation, helping thousands of people around the world communicate and connect in ways once thought impossible," Steele told Stockhead. Control Bionics has developed the NeuroNode – a wearable, watch-like, wireless non-invasive electromyography (EMG) and spatial sensor device to assist cognitive people with physical disabilities perform everyday functions. He said NeuroNode was globally unique as the only augmentative and alternative communication (AAC) technology of its kind that combined movement and EMG signals into a single platform. "Recognition by the US Centers for Medicare & Medicaid Services, awarding NeuroNode the first HCPCS code for an AAC device in 13 years, validates both the technology and the profound impact it delivers," he said. "We're proud to be a pioneer in the fast-emerging neurotechnology space, empowering people living with conditions like ALS, cerebral palsy and spinal cord injury to reclaim their voice and their independence." Steele said the company's objective was simple but ambitious – to expand global access to the most advanced, intuitive and life-changing assistive technologies available today. "The NeuroNode isn't just a device, it's a lifeline to communication, control and connection," he said. "We believe that every person – regardless of physical ability — deserves a way to engage with the world. "Our team's work over two decades reflects a deep commitment to designing technologies that break through barriers and restore possibility."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store